Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Zihua Zeng, M.D.

Zihua Zeng, M.D.


Zihua Zeng M.D.

Zihua Zeng, M.D.

Research Associate
The Methodist Hospital Research Institute

Phone: 713-441-3592
Fax: 713-790-2681
E-mail: zzeng@houstonmethodist.org


M.D.   Guangzhou Medical College, Guangzhou, China (Clinical Medicine)
M.Sc.   Medical College of Jinan University, Guangzhou, China (Pathology)

Postdoctoral Training

Postdoctoral Associate, The Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX



After earning his M.D. and M.Sc. degrees, Dr. Zeng worked in the department of pathology of the Medical College of Jinan University in Guangzhou, China, where he practiced pathology and conducted cancer research. His research experience is in carcinogenesis, cancer metastasis and the development of cancer treatment models. Dr. Zeng continued his research at the Institute of Pathology of the Free University in Berlin, Germany from 1997 to 2000 as a visiting scholar. He used cDNA array techniques for gene expression profiling of CD30+ lymphomas, including Hodgkin's lymphoma and anaplastic large cell lymphoma, after treatment with single chain anti-CD30 antibody. From May 2006 to Nov 2007, Dr. Zeng worked in the Center for Cell and Gene Therapy of Baylor College of Medicine on strategies to enhance virotherapy for solid cancers. He joined the laboratory of Dr. Youli Zu at TMHRI in 2007 to develop gene therapy for human anaplastic large cell ymphoma (ALCL).

Description of Research

Dr. Zeng's current studies focus on using fluorescence-labeled oligonucleotide aptamers to target ALCL cells in vivo for xenograft ALCL models and improving methods for specifically targeting ALCL tumors with nanotechnology-based therapy. He plans to use stable ALCL and control cell lines expressing GFP and luciferase to track tumor growth and metastasis in vivo, and assess the efficacy of multiple therapies with live scanning bioluminescent signals from visible or undetectable tumor nodules. An additional goal of this research is to characterize signaling pathway events that are generated by aptamer-CD30 coupling, other than by CD30-CD30 antibody or CD30-CD30L interactions, in order to identify potential mechanisms to enhance the efficacy of ALCL therapies.

Major Areas of Research

ACLC, nanotechnology, metastasis, aptamers, xenograft models

Recent Publications

McDonnell SR, Hwang SR, Basrur V, Conlon KP, Fermin D, Wey E, Murga-Zamalloa C, Zeng Z, Zu Y, Elenitoba-Johnson KS, Lim MS. NPM-ALK signals through glycogen synthase kinase 3ß to promote oncogenesis. Oncogene. 2012 Aug 9;31(32):3733-40.

Zhao N, Qi J, Zeng Z, Parekh P, Chang CC, Tung CH, Zu Y. Transfecting the hard-to-transfect lymphoma/leukemia cells using a simple cationic polymer nanocomplex. J Control Release. 2012 Apr 10;159(1):104-10.

Zhang P, Zhao N, Zeng Z, Chang CC, Zu Y. Combination of an aptamer probe to CD4 and antibodies for multicolored cell phenotyping. Am J Clin Pathol. 2010 Oct;134(4):586-93.

Zeng Z, Zhang P, Zhao N, Sheehan AM, Tung CH, Chang CC, Zu Y.Using oligonucleotide aptamer probes for immuno-staining of formalin fixed and paraffin-embedded tissues. Mod Pathol. 2010 Dec;23(12):1553-8.

Ito M, Zhao N, Zeng Z, Chang CC, Zu Y. Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126. Cancer Gene Ther. 2010 Sep;17(9):633-44.

Zhang P, Zhao N, Zeng Z, Feng Y, Tung CH, Chang CC and Zu Y. Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. Lab Invest. 2009;89:1423-32.

Li H, Zeng Z, Fu X, Zhang X. Coadministration of an HSV-2-based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res. 2007;67:7850-5

Jiang X, Zeng Z, Zhou X, Wang Q. A study on the expression of HPV, VEGF and ER in the cervical carcinoma and its precancerous lesions. Chin J Clin Oncol Rehabil. 2007;14:389-392.

Liu F, Zeng Z, Zhou X, Li H. The expression of TSG 101 gene in cervical carcinoma, endometrial carcinoma of uterus and ovary carcinoma. Guangdong Med J. 2007;28:363-364.